0 464

Cited 9 times in

Prognostic factors in small cell lung cancer: a new prognostic index in Korean patients

Authors
 Hong S.  ;  Cho B.C.  ;  Choi H.J.  ;  Jung M.  ;  Lee S.H.  ;  Park K.S.  ;  Kim S.K.  ;  Kim J.H. 
Citation
 ONCOLOGY, Vol.79(3-4) : 293-300, 2010 
Journal Title
ONCOLOGY
ISSN
 0030-2414 
Issue Date
2010
MeSH
Adult ; Aged ; Aged, 80 and over ; Antigens, Neoplasm/metabolism ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Bone Neoplasms/drug therapy ; Bone Neoplasms/mortality ; Bone Neoplasms/secondary ; Brain Neoplasms/drug therapy ; Brain Neoplasms/mortality ; Brain Neoplasms/secondary ; Carcinoma, Squamous Cell/drug therapy ; Carcinoma, Squamous Cell/mortality* ; Carcinoma, Squamous Cell/pathology ; Female ; Follow-Up Studies ; Humans ; Keratin-19/metabolism ; Liver Neoplasms/drug therapy ; Liver Neoplasms/mortality ; Liver Neoplasms/secondary ; Lung Neoplasms/drug therapy ; Lung Neoplasms/mortality* ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Staging ; Prognosis ; Republic of Korea ; Retrospective Studies ; Small Cell Lung Carcinoma/drug therapy ; Small Cell Lung Carcinoma/mortality* ; Small Cell Lung Carcinoma/pathology ; Survival Rate ; Survivors*
Keywords
CYFRA 21-1 ; Disease extent ; Performance status ; Prognostic factors ; Small cell lung cancer ; Survival
Abstract
OBJECTIVE: The aims of this study were to identify prognostic factors for overall survival (OS) in patients with small cell lung cancer (SCLC) and to construct a prognostic index on the basis of their expected OS. Long-term survivors were also given special attention.

METHODS: We retrospectively analyzed 295 patients diagnosed with SCLC from January 2002 to September 2007 at the Severance Hospital, Seoul, Republic of Korea. Patient history was reviewed regarding both clinical and tumor-related markers, and treatment-related factors were also evaluated.

RESULTS: There were 131 (44.4%) patients with limited disease (LD) and 164 (55.6%) with extensive disease (ED). Median follow-up lasted 9.4 months. Objective response to chemotherapy was 66.8%. The median survival time (MST) was 11.2 months in all patients, 20.4 months in LD patients, and 7.7 months in ED patients. The median progression-free survival was 9.4 months. Independent prognostic factors for overall survival (OS) were extent of disease, performance status, and CYFRA 21-1 level. We classified all patients into four groups based on the results of multivariate analysis using classification and regression tree analysis. Median survival times were 22.7, 13.7, 8.5, and 3.2 months, respectively. A total of 51 (17.3%) patients from the entire study population were evaluated for long-term survival, which was defined as survival >2 years. Their MST was 43.1 months, and extent of disease, performance status, and CYFRA 21-1 were independent prognostic factors for long-term survival.

CONCLUSIONS: We confirmed the well-known prognosticators, disease extent and performance status, in our patients, but further identified CYFRA 21-1 as independent prognostic factor. A prognostic index was constructed to create four classifications of SCLC considering these variables
Full Text
http://www.karger.com/Article/FullText/323333
DOI
10.1159/000323333
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pharmacology (약리학교실) > 1. Journal Papers
Yonsei Authors
Kim, Se Kyu(김세규)
Kim, Joo Hang(김주항)
Park, Kyungsoo(박경수) ORCID logo https://orcid.org/0000-0002-6972-1143
Lee, Soo Hyeon(이수현)
Jung, Min Kyu(정민규) ORCID logo https://orcid.org/0000-0001-8281-3387
Cho, Byoung Chul(조병철) ORCID logo https://orcid.org/0000-0002-5562-270X
Choi, Hye Jin(최혜진) ORCID logo https://orcid.org/0000-0001-5917-1400
Hong, Soo Jung(홍수정)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/103141
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links